• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.

作者信息

Chen Vincent L, Morgan Timothy R, Rotman Yaron, Patton Heather M, Cusi Kenneth, Kanwal Fasiha, Kim W Ray

机构信息

Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.

Division of Gastroenterology, University of California Irvine, Irvine, CA, USA.

出版信息

Hepatology. 2025 Jan 1;81(1):312-320. doi: 10.1097/HEP.0000000000001112. Epub 2024 Oct 18.

DOI:10.1097/HEP.0000000000001112
PMID:39422487
Abstract
摘要

相似文献

1
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.用于代谢功能障碍相关脂肪性肝病的瑞美替隆疗法：美国肝病研究学会实践指南2024年10月更新
Hepatology. 2025 Jan 1;81(1):312-320. doi: 10.1097/HEP.0000000000001112. Epub 2024 Oct 18.
2
Erratum: Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.勘误：用于代谢功能障碍相关脂肪性肝病的瑞美替昂治疗：2024年10月美国肝病研究学会实践指南更新
Hepatology. 2025 Apr 1;81(4):E133. doi: 10.1097/HEP.0000000000001186. Epub 2025 Feb 12.
3
Letter to the Editor: Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease-October 2024 updates to AASLD practice guidance.致编辑的信：用于代谢功能障碍相关脂肪性肝病的雷斯美洛治疗——2024年10月美国肝病研究学会实践指南更新
Hepatology. 2025 Jun 1;81(6):E158-E159. doi: 10.1097/HEP.0000000000001264. Epub 2025 Feb 17.
4
Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis.选择性甲状腺激素受体-β激动剂 Resmetirom 治疗代谢功能障碍相关脂肪性肝病（MASLD）的疗效和安全性：系统评价和荟萃分析。
Sci Rep. 2024 Aug 26;14(1):19790. doi: 10.1038/s41598-024-70242-8.
5
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.代谢相关脂肪性肝病：新命名对美国肝病研究学会非酒精性脂肪性肝病实践指南的影响及更新。
Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670. Epub 2023 Nov 9.
6
Resmetirom: The First Food and Drug Administration-Approved Medication for Nonalcoholic Steatohepatitis (NASH).瑞美替隆：首个获美国食品药品监督管理局批准用于治疗非酒精性脂肪性肝炎（NASH）的药物。
Ann Pharmacother. 2025 Feb;59(2):162-173. doi: 10.1177/10600280241259528. Epub 2024 Jun 17.
7
Resmetirom in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Comprehensive Review of Current Evidence and Therapeutic Potential.Resmetirom用于治疗代谢功能障碍相关脂肪性肝炎（MASH）：当前证据与治疗潜力的全面综述
Cureus. 2024 Nov 29;16(11):e74772. doi: 10.7759/cureus.74772. eCollection 2024 Nov.
8
Hepatic thyroid hormone receptor-β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis.肝脏甲状腺激素受体-β信号传导：代谢功能障碍相关脂肪性肝炎治疗的机制与最新进展
Diabetes Obes Metab. 2025 Apr;27(4):1635-1647. doi: 10.1111/dom.16117. Epub 2024 Dec 10.
9
Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis.专家组建议：在伴有 MASH/NASH 和中至非肝硬化晚期纤维化的患者中起始和监测雷美替胺的临床实用应用。
Clin Gastroenterol Hepatol. 2024 Dec;22(12):2367-2377. doi: 10.1016/j.cgh.2024.07.003. Epub 2024 Jul 20.
10
The first MASH drug therapy on the horizon: Current perspectives of resmetirom.地平线上的首个 MASH 药物治疗：雷美替胺的当前观点。
Liver Int. 2024 Jul;44(7):1526-1536. doi: 10.1111/liv.15930. Epub 2024 Apr 5.

引用本文的文献

1
Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis.Resmetirom用于代谢功能障碍相关脂肪性肝病和脂肪性肝炎的治疗。
Life (Basel). 2025 Aug 18;15(8):1306. doi: 10.3390/life15081306.
2
Impact of Short-Term Liraglutide Therapy on Non-Invasive Markers of Liver Fibrosis in Patients with MASLD.短期利拉鲁肽治疗对非酒精性脂肪性肝病合并代谢功能障碍患者肝纤维化无创指标的影响
Metabolites. 2025 Jul 31;15(8):510. doi: 10.3390/metabo15080510.
3
MAFLD: A Comprehensive Review of the Link Between Metabolic Dysfunction and Cardiovascular Risk.
MAFLD：代谢功能障碍与心血管风险之间联系的全面综述
Hepat Med. 2025 Aug 19;17:75-90. doi: 10.2147/HMER.S506402. eCollection 2025.
4
Quantitative MRI for Early Treatment Response in MASLD.用于评估非酒精性脂肪性肝病早期治疗反应的定量磁共振成像
Radiology. 2025 Aug;316(2):e252218. doi: 10.1148/radiol.252218.
5
Lipid Accumulation and Insulin Resistance: Bridging Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease.脂质蓄积与胰岛素抵抗：连接代谢功能障碍相关脂肪性肝病和慢性肾脏病
Int J Mol Sci. 2025 Jul 20;26(14):6962. doi: 10.3390/ijms26146962.
6
Resmetirom for Steatotic Liver Disease: Does Data Support Widespread Use?用于脂肪性肝病的瑞美替隆：数据是否支持广泛使用？
Curr Gastroenterol Rep. 2025 Jul 22;27(1):53. doi: 10.1007/s11894-025-01002-5.
7
Trends and demographic disparities in heart failure mortality rates in non-alcoholic fatty liver disease: a population-based retrospective study in the United States from 1999 to 2020.非酒精性脂肪性肝病中心力衰竭死亡率的趋势及人口统计学差异：一项基于美国1999年至2020年人口的回顾性研究。
Am J Cardiovasc Dis. 2025 Jun 15;15(3):166-174. doi: 10.62347/MCPC3010. eCollection 2025.
8
Efficacy of orlistat for the treatment of metabolic dysfunction-associated steatotic liver disease patients: A systematic review and meta-analysis.奥利司他治疗代谢功能障碍相关脂肪性肝病患者的疗效：一项系统评价和荟萃分析。
Hepatol Forum. 2025 May 22;6(3):129-136. doi: 10.14744/hf.2024.2024.0047. eCollection 2025.
9
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs.老年人脂肪性肝病：临床意义与未满足的需求
Nutrients. 2025 Jun 30;17(13):2189. doi: 10.3390/nu17132189.
10
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders.肠促胰岛素与代谢相关脂肪性肝病：内分泌与肝脏疾病的交汇点
Curr Obes Rep. 2025 Jun 25;14(1):56. doi: 10.1007/s13679-025-00646-8.